抗病毒口服液药效学研究

目的：通过动物实验研究抗病毒口服液药效学。方法：细菌内毒素致家兔产生发热模型后不同时间体温波动情况、对流感病毒所致小鼠肺部病变和病毒增殖的影响、测定小鼠最大耐受量。结果：以0．193g/kg抗病毒口服液ig后，家兔体温变化与0．6105g/kg双黄连口服液组比较在0．5h即有差异；与模型对照组比较，高、中、低剂量组均有明显差异，且能维持4h降低体温。小鼠感染病毒后口服本品与模型对照组比较能显著降低动物死亡率（P＜0．05），平均生活日数延长。但死亡保护率低于病毒唑。本品及病毒唑组，肺病变程度和肺指数均显著低于模型对照组（P＜0．05），但其治疗效果不及病毒唑。小鼠最大耐受量不及病毒唑。小鼠最大耐受量倍数为人用量的125倍。结论：抗病毒口服液能明显降低由细菌内毒素所致的发热，具有清热解毒作用；能有效抑制病毒性肺部感染；安全无毒。

Study on the Pharmacodynamics of Kangbingdu Oral Liquid

AIM\ The purpose is to study the pharmacodynamics of Kangbingdu oral liquid (KOL) through animal experiment. METHODS\ The variation in temperature of fevered rabbit induced by endotoxin, the effect of KOL on the pulmonary lesion in mice induced by influenza virus and virus proliferation, and the determination of the maximum tolerance dose of mice were found. RESULTS\ The variation in temperature of rabbit treated by KOL 0.193 g/kg differed from that treated by Shuanghuanglian oral liquid 0.6105 g/kg within half an hour. There was significant difference between the three dosage groups compared with the controlled model group. A descent of temperature lasted four hours. After infected by virus the mortality of mice receiving KOL was remarkably lower than that of the controlled model group ( P <0.05). The average survival time was prolonged but the rate of death protection was lower than that of Virazole group. As for KOL group and Virazole group, the degree of the pulmonary lesion and the pulmonary index were much lower than that of the controlled model group ( P <0.05). But KOL was less effective compared with Virazole. The maximum tolerance dose of mice was 125 times of that of human. CONCLUSION\ Available experiment data indicated that KOL was a safe and nontoxic drug for clearing away heat and toxic material. It can markedly decrease fever induced by endotoxin and effectively inhibit viral pulmonary infection.